基于尿游离皮质醇的个体化无创诊断算法用于ACTH依赖性库欣综合征
该回顾性研究纳入法国2家医院2001至2023年间的247例库欣病(CD)和36例异位ACTH分泌(EAS)患者,并以比利时单中心105例患者作为外部验证。24小时尿游离皮质醇(UFC)区分CD与EAS的ROC曲线下面积最高( primary study .96 [95%CI .92-.99],验证队列 .99 [95%CI .98-1.00])。基于基线UFC将患者分为3组(<3、3-10、>10倍正常上限),EAS患病率分别为0%、6.1%和66.7%,并据此提出个体化无创诊断流程。
要点
- 24小时尿游离皮质醇(UFC)区分库欣病与异位ACTH分泌的ROC曲线下面积在 primary study 为.96(95%CI .92-.99),验证队列为.99(95%CI .98-1.00)。
- 基于基线UFC分组:<3倍正常上限组EAS患病率0%,3-10倍组6.1%,>10倍组66.7%。
- 本队列支持的诊断流程:第1组单用垂体MRI;第2组先MRI,阴性后行颈至盆腔CT(npCT);第3组先npCT,阴性后行垂体MRI。
核心结论
- UFC能准确预测异位ACTH分泌,并可用于定义个体化无创诊断算法。
研究设计与样本
- 回顾性研究,纳入法国2家大学医院2001至2023年间评估的247例库欣病患者和36例异位ACTH分泌患者。
- 比利时单中心105例患者队列作为外部验证。
主要发现
- 24小时尿游离皮质醇(UFC)区分库欣病与异位ACTH分泌的ROC曲线下面积在 primary study 为.96(95%CI .92-.99),在验证队列为.99(95%CI .98-1.00)。
- 在UFC基础上加临床、影像和生化参数未较单用UFC改善EAS预测,仅BIPPS显示适度改善(C-statistic指数.99 [95%CI .97-1.00])。
- 基于基线UFC分组:<3倍正常上限(第1组)、3-10倍(第2组)、>10倍(第3组)的EAS患病率分别为0%、6.1%和66.7%。
- 去氨加压素试验不与CRH试验联合时诊断价值有限。
关键数值与推荐
- 第1组(UFC<3倍正常上限):单用垂体MRI。
- 第2组(UFC 3-10倍正常上限):先垂体MRI,阴性后行颈至盆腔CT(npCT)。
- 第3组(UFC>10倍正常上限):先npCT,阴性后行垂体MRI。
临床怎么用
- 本队列支持的诊断流程为:第1组单用垂体MRI;第2组先MRI,阴性后行npCT;第3组先npCT,阴性后行垂体MRI。
- 去氨加压素试验不与CRH试验联合时诊断价值有限。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Current guidelines for distinguishing Cushing's disease (CD) from ectopic ACTH secretion (EAS) are questionable, as they use pituitary magnetic resonance imaging (MRI) as first-line investigation for all patients. CRH testing is no longer available, and they suggest performing inferior petrosal sinus sampling (BIPPS), an invasive and rarely available investigation, in many patients. OBJECTIVE: To establish noninvasive personalized diagnostic strategies based on the probability of EAS estimated from simple baseline parameters. DESIGN: Retrospective study. SETTING: University hospitals. PATIENTS: Two hundred forty-seven CD and 36 EAS patients evaluated between 2001 and 2023 in 2 French hospitals. A single-center cohort of 105 Belgian patients served as external validation. RESULTS: Twenty-four-hour urinary free cortisol (UFC) had the highest area under the receiver operating characteristic curve for discrimination of CD from EAS (.96 [95% confidence interval (CI), .92-.99] in the primary study and .99 [95% CI, .98-1.00] in the validation cohort). The addition of clinical, imaging, and biochemical parameters did not improve EAS prediction over UFC alone, with only BIPPS showing a modest improvement (C-statistic index .99 [95% CI, .97-1.00]). Three groups were defined based on baseline UFC: < 3 (group 1), 3-10 (group 2), and > 10 × the upper limit of normal (group 3), and they were associated with 0%, 6.1%, and 66.7% prevalence of EAS, respectively. Diagnostic approaches performed in our cohort support the use of pituitary MRI alone in group 1, MRI first followed by neck-to-pelvis computed tomography scan (npCT) when negative in group 2, and npCT first followed by pituitary MRI when negative in group 3. When not combined with the CRH test, the desmopressin test has limited diagnostic value. CONCLUSION: UFC accurately predicts EAS and can serve to define personalized and noninvasive diagnostic algorithms.
引用
- Lavoillotte J, Mohammedi K, Salenave S, et al. Personalized Noninvasive Diagnostic Algorithms Based on Urinary Free Cortisol in ACTH-dependant Cushing's Syndrome. J Clin Endocrinol Metab. 2024. PMID: 38609171. doi:10.1210/clinem/dgae258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。